公开(公告)号：US20250057952A1

公开(公告)日：2025-02-20

申请号：US18562603

申请日：2022-05-23

Applicant: CELLECTIS S.A.

Inventor： Shipra DAS ,  Julien VALTON ,  Laurent POIROT ,  Philippe DUCHATEAU

IPC: A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C12N15/90

Abstract: The invention relates to methods of treatment of a solid tumor in a patient in need thereof, comprising administering to the patient: (i) an effective amount of engineered immune cells originating from a donor expressing at their cell surface a Chimeric Antigen Receptor (CAR) directed against Fibroblast Activation Protein (FAP), and (ii) an effective amount of an immunotherapy treatment that elicits an immune response in the patient.

公开(公告)号：US20250034641A1

公开(公告)日：2025-01-30

申请号：US18914680

申请日：2024-10-14

Applicant: CELLECTIS

Inventor： David SOURDIVE ,  Aymeric DUCLERT ,  Mathieu SIMON ,  Philippe DUCHATEAU ,  Alan Marc WILLIAMS ,  Laurent POIROT

IPC: C12Q1/6881 ,  A61K39/00

Abstract: The present invention provides composition kits and methods for treating cancer in a human by immunotherapy using successive doses of CAR-T cells with no or reduced anamnestic immune reaction in one individual (P).

公开(公告)号：US12144825B2

公开(公告)日：2024-11-19

申请号：US16625678

申请日：2018-07-02

Applicant: CELLECTIS

Inventor： David Sourdive ,  Aymeric Duclert ,  Mathieu Simon ,  Philippe Duchateau ,  Alan Marc Williams ,  Laurent Poirot

IPC: A61K35/17 ,  A61K39/00 ,  C12Q1/6881

Abstract: The present invention provides composition kits and methods for treating cancer in a human by immunotherapy using successive doses of CAR-T cells with no or reduced anamnestic immune reaction in one individual (P).

公开(公告)号：US20240318154A1

公开(公告)日：2024-09-26

申请号：US18561938

申请日：2022-05-20

Applicant: CELLECTIS ,  Albert-Ludwigs-Universitat Freiburg

Inventor： Toni CATHOMEN ,  Tatjana CORNU ,  Julia KLERMUND ,  Manuel RHIEL ,  Julia ROSITZKA ,  Philippe DUCHATEAU ,  Alexandre JUILLERAT

IPC: C12N9/22 ,  A61K35/28 ,  C07K14/47 ,  C12N5/0789 ,  C12N15/90

CPC classification number: C12N9/22 ,  A61K35/28 ,  C07K14/4705 ,  C12N5/0647 ,  C12N15/907 ,  C12N2510/00

Abstract: The present invention generally relates to the field of genome engineering (gene editing), and more specifically to gene therapy for the treatment of Severe Combined Immunodeficiency (SCID) related to RAG1. Particularly, the present invention pertains to the treatment of RAG1 deficiency in long-term repopulating hematopoietic stem cells (HSCs). The present invention provides means and methods for genetically modifying HSCs involving gene editing reagents, such as TALE-nucleases, that specifically target a non-functional endogenous RAG1 gene, comprising at least one mutation causing Severe Combined Immunodeficiency (SCID), thereby allowing the restoration of the normal cellular phenotype. The present invention also provides engineered RAG1-edited HSCs comprising an exogenous sequence comprising a nucleic acid sequence encoding a functional RAG1 protein which is integrated in said HSCs' genome into a non-functional RAG1 endogenous locus, resulting in the expression of a functional RAG1 polypeptide. The present invention further provides populations of cells comprising said engineered HSCs, pharmaceutical compositions comprising said engineered HSCs or populations of cells, as well as their use in gene therapy for the treatment of Severe Combined Immunodeficiency (SCID) related to RAG1.

公开(公告)号：US20230357719A1

公开(公告)日：2023-11-09

申请号：US18321481

申请日：2023-05-22

Applicant: Cellectis

Inventor： Philippe DUCHATEAU ,  Laurent POIROT

IPC: C12N5/0783 ,  A61K35/17 ,  A61P35/02 ,  A61P35/00

CPC classification number: C12N5/0636 ,  A61K35/17 ,  A61P35/02 ,  A61P35/00 ,  C12N2510/00 ,  C12N2501/599 ,  Y02A50/30

Abstract: Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said immune cells (ex: CD38, CSI or CD70) by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.

公开(公告)号：US20230228739A1

公开(公告)日：2023-07-20

申请号：US18002229

申请日：2021-07-02

Applicant: CELLECTIS S.A.

Inventor： Xenia NAJ ,  Anne-Sophie Petit ,  Roman Galetto ,  Jean-Pierre Cabaniols

IPC: G01N33/50 ,  G01N33/574 ,  G01N33/566

CPC classification number: G01N33/505 ,  G01N33/574 ,  G01N33/566 ,  G01N2800/7028

Abstract: The invention relates to a new potency assay for characterizing the quality and activity of an immune cell expressing a chimeric antigen receptor, the kit to carry out this assay and uses thereof.

公开(公告)号：US11690873B2

公开(公告)日：2023-07-04

申请号：US16498276

申请日：2018-03-30

Applicant: CELLECTIS SA

Inventor： Cecile Schiffer-Mannioui ,  Philippe Duchateau ,  Anne-Sophie Gautron

IPC: C07K14/705 ,  C07K19/00 ,  A61P35/00 ,  A61K39/395 ,  A61K35/17 ,  C07K14/725 ,  C07K16/28 ,  A61P35/02 ,  A61K31/365

CPC classification number: A61K35/17 ,  A61K31/365 ,  A61K39/39558 ,  A61P35/02 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/2803 ,  C07K2317/34 ,  C07K2317/53 ,  C07K2317/622

Abstract: The present invention relates to new CD22 Chimeric Antigen Receptors (CD22 CAR), an engineered immune cell endowed with said new CD22 CAR and comprising at least inactivated TRAC gene for use in therapy. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.

公开(公告)号：US20230158070A1

公开(公告)日：2023-05-25

申请号：US16965834

申请日：2019-01-30

Applicant: CELLECTIS

Inventor： Philippe DUCHATEAU

IPC: A61K35/17 ,  C07K14/725 ,  C07K16/28

CPC classification number: A61K35/17 ,  C07K14/7051 ,  C07K16/2803 ,  A61K2039/505

Abstract: The present invention relates to a therapeutic combination of immune cells, preferably allogeneic non-alloreactive TCR-KO immune T cells, wherein a gene coding an antigen marker X present on both T-cells and pathological cells is inactivated and a corresponding therapeutic antibody specific for said antigen marker X, method for preparing the same and use in immunotherapy.

公开(公告)号：US20230056268A1

公开(公告)日：2023-02-23

申请号：US17716102

申请日：2022-04-08

Applicant: CELLECTIS

Inventor： Roman GALETTO ,  Agnes GOUBLE ,  Stephanie GROSSE ,  Cécile SCHIFFER-MANNIOUI ,  Laurent POIROT ,  Andrew SCHARENBERG ,  Julianne SMITH

IPC: A61K35/17 ,  C12N9/22 ,  C12N5/0783

Abstract: The present invention relates to methods for developing engineered T-cells for immunotherapy and more specifically to methods for modifying T-cells by inactivating at immune checkpoint genes, preferably at least two selected from different pathways, to increase T-cell immune activity This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to highly efficient adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US11414674B2

公开(公告)日：2022-08-16

申请号：US16361438

申请日：2019-03-22

Applicant: Cellectis

Inventor： Roman Galetto ,  Agnes Gouble ,  Stephanie Grosse ,  Cecile Mannioui ,  Laurent Poirot ,  Andrew Scharenberg ,  Julianne Smith

IPC: A61K35/17 ,  C12N15/85 ,  C07K14/705 ,  C12N5/0783 ,  C07K14/725 ,  C07K16/28 ,  A61K39/00 ,  A61K38/00

Abstract: A method of expanding deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.